The Zhitong Finance App learned that on Friday, Zaiding Pharmaceutical (ZLAB.US) rose nearly 10% at the beginning of the session. As of press release, it had risen more than 2% to $22.62. According to the news, on October 23, Zaiding Pharmaceutical announced global phase Ib clinical research data for its antibody-conjugated drug (ADC) Zocilurtatug Pelitecan (“Zoci”, original code name ZL-1310) for first-line broad-stage small cell lung cancer. The relevant results will be presented at the 2026 European Society of Medical Oncology (ESMO) conference on October 26.

The Zhitong Finance App learned that on Friday, Zaiding Pharmaceutical (ZLAB.US) rose nearly 10% at the beginning of the session. As of press release, it had risen more than 2% to $22.62. According to the news, on October 23, Zaiding Pharmaceutical announced global phase Ib clinical research data for its antibody-conjugated drug (ADC) Zocilurtatug Pelitecan (“Zoci”, original code name ZL-1310) for first-line broad-stage small cell lung cancer. The relevant results will be presented at the 2026 European Society of Medical Oncology (ESMO) conference on October 26.